Navigation Links
Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
Date:4/29/2008

ing time to tumor progression, duration of response, overall patient survival and safety parameters. Patients may continue to receive bavituximab alone after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable.

Tumor response in this study will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. The trial is being conducted in the Republic of Georgia according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards.

The National Cancer Institute estimates that approximately 178,480 U.S. women were diagnosed with cancer of the breast in 2007 and about 40,460 women died of the disease. According to the World Health Organization, breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is usually located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase Ib pilot trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. Peregrine has received regulatory approval to conduct three Phase II trials to study the anti-tumor effects of bavituximab in combination with chemotherapy. These include two breast cancer protocols and a non-small cell lung cancer protocol. Bavituximab is in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.

'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
2. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
3. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
4. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
5. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
6. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Ind., July 30, 2015 , Net Sales ... the prior year period and an increase of 5.7% constant ... second quarter was $(0.91), and adjusted earnings per share were ... , Company updates guidance Zimmer Biomet ... for the quarter ended June 30, 2015.  The Company reported ...
(Date:7/29/2015)... 30, 2015 Roche (SIX: RO, ROG; OTCQX: ... EGFR Mutation Test v2 for Premarket Approval (PMA) ... as a companion diagnostic test for AZD9291, an ... patients with an acquired resistant mutation.  ... have adenocarcinoma with tumor containing an EGFR sensitizing ...
(Date:7/29/2015)... YORK, Pa. , July 29, 2015  Unilife ... and ASX: UNS), a developer, manufacturer and supplier of ... a multifaceted financing strategy that provides the Company with ... Unilife has signed an equity purchase ... Capital Fund, LLC ("LPC"), a Chicago ...
Breaking Medicine Technology:Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 2Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 3Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 4Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 5Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 6Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 7Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 8Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 9Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 10Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 11Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 12Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 13Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 14Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 15Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 16Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 17Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 18Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 19Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 20Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 21Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 22Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 23Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 24Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 25Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 26Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 27Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 28Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 29Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 2Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 3Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5
... 2011 Genelux Corporation, a privately held, clinical stage ... and inflammatory diseases, today announced the appointment of Dr. ... Board of Directors. "In a career defined ... unique set of skills and attributes that we believe ...
... 4, 2011 /PRNewswire-Asia/ -- Global Pharm Holdings Group, ... China-based growing vertically integrated pharmaceutical company engaged in ... herbs cultivation and processing business through its subsidiaries ... that, on August 1, 2011, the Company entered ...
Cached Medicine Technology:Genelux Corporation Appoints Catherine J. Mackey, PhD to Board of Directors 2Global Pharm Holdings Group Completes Acquisition of Pacific Asia Pharm Investment Group Co., Ltd. 2Global Pharm Holdings Group Completes Acquisition of Pacific Asia Pharm Investment Group Co., Ltd. 3Global Pharm Holdings Group Completes Acquisition of Pacific Asia Pharm Investment Group Co., Ltd. 4Global Pharm Holdings Group Completes Acquisition of Pacific Asia Pharm Investment Group Co., Ltd. 5
(Date:7/30/2015)... ... July 30, 2015 , ... ... one of the largest, family-owned low cost service and repair companies. For 35 ... as well as growing their company to meet the demands of the changing ...
(Date:7/30/2015)... ... , ... The need for accessibility is never greater than when we find ... well as visiting friends and family during these critical moments, hospitals around the Pennsylvania ... powered by ChargeItSpot , a Philadelphia-based startup that recently secured a $4M Series ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... the ‘Mary Jo Lawyer-Spano Mesothelioma Patient Registry Act of 2015’. The bill ... Chris Collins (R-NY), Peter King (R-NY), Betty McCollum (D-MN), Joe Kennedy (D-MA), and ...
(Date:7/30/2015)... ... 2015 , ... On July 23rd Clay Today Online reported the ... state’s large prison system, which has amassed largely enough throughout the years. Florida is ... of President Obama’s recent reduction of non violent drug offender’s prison sentences, Florida is ...
(Date:7/30/2015)... Alexandria, VA (PRWEB) , ... July 30, 2015 ... ... applauds Drug Enforcement Administration (DEA) Acting Administrator Chuck Rosenberg’s announcement of the reinstitution ... been scheduled for Saturday, September 26, 2015 from 10:00 AM to 2:00 PM ...
Breaking Medicine News(10 mins):Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 2Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 3Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3
... employed in dentistry, this method of accelerated tissue healing is showing its ... ... April 14, 2009 -- It was first used by dental surgeons about ... reconstructive surgery. Platelet Rich Plasma (PRP) therapy is today being ...
... Distress (FMD), defined as having 14 or more days in ... not good , is not evenly distributed across the United ... consistently low FMD incidence, as shown in a study published ... of Preventive Medicine . , Combining data from annual large-scale ...
... Angeles Lakers Star Luke Walton Rallies Students to Get Fit ... GrantLOS ANGELES, April 13 Los Angeles Lakers star Luke ... fitness game as part of a new national campaign called ... of a new partnership between the "got milk?" Body By ...
... Community members join The Help Group,s Statewide efforts to ... Help Group, the nation,s largest and most comprehensive ... other special needs , recently launched its annual California ... Autism Awareness Month. Today it is estimated that one ...
... MILWAUKEE, April 13 (Logo: http://www.newscom.com/cgi-bin/prnh/20090303/CG78204LOGO-b ) WHAT: ... will be the first hospital system in ... knee replacement surgery on the Internet. Through the ... running commentary, updates of activities and photos of the ...
... of the drug used to treat chronic myeloid leukemia ... first treated with a drug known as imatinib mesylate. ... becomes resistant to the drug. However, a team of ... Thomas Jefferson University, Philadelphia, has identified a class of ...
Cached Medicine News:Health News:Singapore First in Southeast Asia to Use Novel Treatment for Sports and Musculoskeletal Injuries 2Health News:Singapore First in Southeast Asia to Use Novel Treatment for Sports and Musculoskeletal Injuries 3Health News:Singapore First in Southeast Asia to Use Novel Treatment for Sports and Musculoskeletal Injuries 4Health News:Where you live may affect your state of mind 2Health News:got milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Marina Del Rey Middle School in Los Angeles 2Health News:got milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Marina Del Rey Middle School in Los Angeles 3Health News:got milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Marina Del Rey Middle School in Los Angeles 4Health News:got milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Marina Del Rey Middle School in Los Angeles 5Health News:The Help Group Launches Multifaceted Autism Awareness Campaign 2Health News:Aurora St. Luke's Medical Center to Broadcast First Live Surgery Via Twitter in Wisconsin 2Health News:JCI online early table of contents: April 13, 2009 2Health News:JCI online early table of contents: April 13, 2009 3Health News:JCI online early table of contents: April 13, 2009 4Health News:JCI online early table of contents: April 13, 2009 5Health News:JCI online early table of contents: April 13, 2009 6
The clear choice for surgery, foreign body removal,and other delicate work.,Oculus binocular loupes come in 1.8x magnification with a 30 cm working distance--or 2.5x magnification with a choice ...
Eyeglass Loupe 3x-5x made with precision optical glass. Ideal for any detail work....
... designed for computer operators who require ... placed at different heights and distanced ... Card is printed two sided- black ... and uses two type sizes to ...
Near PT test card/child recog/ playing cards 5 1/2" X 8"....
Medicine Products: